Review



dexcom rt cgm systems14 21  (Dexcom Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Dexcom Inc dexcom rt cgm systems14 21
    Dexcom Rt Cgm Systems14 21, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+rt+cgm/cgm+rt/pm41920755-145-12-12
    Average 86 stars, based on 1 article reviews
    dexcom rt cgm systems14 21 - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Control:

    Article Title: Evaluating the Cost-Effectiveness of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in the Treatment of Patients with Insulin-Treated Type 2 Diabetes in Australia
    Article Snippet: .. Dexcom RT-CGM has been shown to significantly improve glycemic control in patients with T2D on multiple daily injections, as evidenced by reductions in HbA1c [ – ]. ..

    Article Title: Evaluating the Cost-Effectiveness of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in the Treatment of Patients with Insulin-Treated Type 2 Diabetes in Australia.
    Article Snippet: .. Dexcom RT-CGM has been shown to significantly improve glycemic control in patients with T2D on multiple daily injections, as evidenced by reductions in HbA1c [12–15]. ..

    other:

    Article Title: Evaluating the Cost-Effectiveness of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in the Treatment of Patients with Insulin-Treated Type 2 Diabetes in Australia.
    Article Snippet: Reducing the HbA1c treatment effect of Dexcom RT-CGM to 0.3 (from the DIAMOND T2D RCT) and 0.392 (a 30% reduction) lowered NMB to AUD 29,624 and AUD 32,538, respectively, while increasing it to 0.728 (30% increase) raised NMB to AUD 42,799 [28].

    Article Title: ATTD Barcelona 2026-11–14 March and ATTD-ASIA 2025 Singapore-9–11 December
    Article Snippet: Cohorts consisted of CGM-naïve PWT2D-IIT or -BIT taking tirzepatide who initiated Dexcom RT-CGM (index=first claim) or did not use CGM (index randomly assigned) between 1/1/2023 and 9/30/2024.

    Article Title: Evaluating the Cost-Effectiveness of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in the Treatment of Patients with Insulin-Treated Type 2 Diabetes in Australia
    Article Snippet: Reducing the HbA1c treatment effect of Dexcom RT-CGM to 0.3 (from the DIAMOND T2D RCT) and 0.392 (a 30% reduction) lowered NMB to AUD 29,624 and AUD 32,538, respectively, while increasing it to 0.728 (30% increase) raised NMB to AUD 42,799 [ ].

    Article Title: ATTD Barcelona 2026-11–14 March and ATTD-ASIA 2025 Singapore-9–11 December
    Article Snippet: Conclusions: Overall, starting a Dexcom RT-CGM was associated with significant reductions in DKA-related hospitalizations and ER visits in both children and adults with T1D.



    Similar Products

    dexcom rt cgm systems14 21  (Dexcom Inc)
    86
    Dexcom Inc dexcom rt cgm systems14 21
    Dexcom Rt Cgm Systems14 21, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+rt+cgm/cgm+rt/pm41920755-145-12-12
    Average 86 stars, based on 1 article reviews
    dexcom rt cgm systems14 21 - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    dexcom g6 rt cgm  (Dexcom Inc)
    86
    Dexcom Inc dexcom g6 rt cgm
    Dexcom G6 Rt Cgm, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+rt+cgm/cgm+rt/10__1177_slash_15209156251412178-13307-10-10
    Average 86 stars, based on 1 article reviews
    dexcom g6 rt cgm - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    dexcom rt cgm  (Dexcom Inc)
    86
    Dexcom Inc dexcom rt cgm
    Dexcom Rt Cgm, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+rt+cgm/cgm+rt/10__1177_slash_15209156251412178-2253-11-11
    Average 86 stars, based on 1 article reviews
    dexcom rt cgm - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    dexcom rt cgm use  (Dexcom Inc)
    86
    Dexcom Inc dexcom rt cgm use
    Dexcom Rt Cgm Use, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+rt+cgm/cgm+rt/10__1177_slash_15209156251412178-2259-1-1
    Average 86 stars, based on 1 article reviews
    dexcom rt cgm use - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    dexcom rt cgm users  (Dexcom Inc)
    86
    Dexcom Inc dexcom rt cgm users
    Net changes in non-insulin medication class count stratified by cohort <t>and</t> <t>RT-CGM</t> use or CGM non-use. “Addition” and “Reduction” categories indicate a net increase or decrease in medications at follow-up compared to baseline. “No Change” indicates the same medication classes were used at baseline and follow-up. “Net Zero Change” indicates the same number of medication classes were added as removed at follow-up compared to baseline. Cohorts are presented as ( A ) T2D-NIT, ( B ) T2D-BIT, and ( C ) T2D-IIT.
    Dexcom Rt Cgm Users, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+rt+cgm/cgm+rt/pmc13012535-82-5-5
    Average 86 stars, based on 1 article reviews
    dexcom rt cgm users - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Net changes in non-insulin medication class count stratified by cohort and RT-CGM use or CGM non-use. “Addition” and “Reduction” categories indicate a net increase or decrease in medications at follow-up compared to baseline. “No Change” indicates the same medication classes were used at baseline and follow-up. “Net Zero Change” indicates the same number of medication classes were added as removed at follow-up compared to baseline. Cohorts are presented as ( A ) T2D-NIT, ( B ) T2D-BIT, and ( C ) T2D-IIT.

    Journal: Diabetes, Metabolic Syndrome and Obesity

    Article Title: Impact of Real-Time Continuous Glucose Monitoring on Medication Use and Glycemic Control in Type 2 Diabetes Across Therapy Regimens

    doi: 10.2147/DMSO.S574769

    Figure Lengend Snippet: Net changes in non-insulin medication class count stratified by cohort and RT-CGM use or CGM non-use. “Addition” and “Reduction” categories indicate a net increase or decrease in medications at follow-up compared to baseline. “No Change” indicates the same medication classes were used at baseline and follow-up. “Net Zero Change” indicates the same number of medication classes were added as removed at follow-up compared to baseline. Cohorts are presented as ( A ) T2D-NIT, ( B ) T2D-BIT, and ( C ) T2D-IIT.

    Article Snippet: Each cohort contained two groups: Dexcom RT-CGM users or CGM non-users and 1:1 propensity score matching was performed to minimize differences between the groups.

    Techniques: Medications

    Proportion of each cohort achieving A1c targets stratified by RT-CGM use or CGM non-use. ( A ) Proportion of NIT cohort achieving A1c goals at follow-up, ( B ) Proportion of BIT cohort achieving A1c goals at follow-up, ( C ) Proportion of IIT cohort achieving A1c goals at follow-up, ( D and E ) Proportion of each cohort with a baseline A1c above the indicated target meeting the target at follow-up. **, p<0.001; ***, p<0.0001.

    Journal: Diabetes, Metabolic Syndrome and Obesity

    Article Title: Impact of Real-Time Continuous Glucose Monitoring on Medication Use and Glycemic Control in Type 2 Diabetes Across Therapy Regimens

    doi: 10.2147/DMSO.S574769

    Figure Lengend Snippet: Proportion of each cohort achieving A1c targets stratified by RT-CGM use or CGM non-use. ( A ) Proportion of NIT cohort achieving A1c goals at follow-up, ( B ) Proportion of BIT cohort achieving A1c goals at follow-up, ( C ) Proportion of IIT cohort achieving A1c goals at follow-up, ( D and E ) Proportion of each cohort with a baseline A1c above the indicated target meeting the target at follow-up. **, p<0.001; ***, p<0.0001.

    Article Snippet: Each cohort contained two groups: Dexcom RT-CGM users or CGM non-users and 1:1 propensity score matching was performed to minimize differences between the groups.

    Techniques: